Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Caps

How do you think KERX will perform against the market?

Add Stock to CAPS Watchlist

All Players

388 Outperform
67 Underperform
 

All-Star Players

33 Outperform
23 Underperform
 

Wall Street

8 Outperform
2 Underperform
 

Top KERX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

carterhiggins (87.04)
Submitted April 04, 2017

This company has a drug that will help patients before they get to complete renal failure. The drug is currently only in use by dialysis patients, once they get general approval for patients that are starting renal failure - the number of possible… More

TerryHogan (99.97)
Submitted October 03, 2018

Just judging by the financials summaries here on the fool, I'd guess this thing is run by either scientists or lawyers. Better off having a numbers person, or maybe an operations person at the helm. Even a people person can work depending on the… More

KERX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about KERX.

Recs

1
Member Avatar TerryHogan (99.97) Submitted: 10/3/2018 12:56:35 AM : Underperform Start Price: $3.17 KERX Score: +4.78

Just judging by the financials summaries here on the fool, I'd guess this thing is run by either scientists or lawyers. Better off having a numbers person, or maybe an operations person at the helm. Even a people person can work depending on the business. But I don't think that's what's going on here.

Recs

0
Member Avatar TMFEBCapital (58.50) Submitted: 10/18/2017 3:22:36 PM : Outperform Start Price: $6.62 KERX Score: -62.55

Potential opportunity to significantly expand addressable market with pending FDA label approval in non-dialysis patients. 62 million plus from Aurixia this year, representing 25% YoY plus quarterly growth Q3/Q4. FDA PDUFA date Nov. 6.

Recs

1
Member Avatar carterhiggins (87.04) Submitted: 4/4/2017 6:12:24 PM : Outperform Start Price: $5.79 KERX Score: -65.29

This company has a drug that will help patients before they get to complete renal failure. The drug is currently only in use by dialysis patients, once they get general approval for patients that are starting renal failure - the number of possible patients will go up 5 fold at least.

Leaderboard

Find the members with the highest scoring picks in KERX.

Score Leader

empreinte

empreinte (34.48) Score: +623.72

The Score Leader is the player with the highest score across all their picks in KERX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MTF108 62.52 8/28/2006 Underperform 3W $12.05 -77.43% +118.02% +195.44 0 Comment
Darbhanga 50.61 5/5/2010 Underperform 3M $6.08 -55.25% +126.03% +181.28 0 Comment
Made4WallStreet 71.45 12/29/2006 Underperform 1Y $13.39 -79.69% +98.15% +177.84 0 Comment
vbaci 30.05 8/24/2010 Underperform 5Y $3.68 -26.09% +150.03% +176.12 0 Comment
Korodas 72.54 9/1/2010 Underperform NS $3.72 -26.88% +144.83% +171.72 0 Comment
zokes10 29.66 4/13/2010 Underperform NS $4.82 -43.57% +121.15% +164.72 0 Comment
zokes101 30.42 4/13/2010 Underperform NS $4.79 -43.22% +121.44% +164.65 0 Comment
CHICAGOREALTOR < 20 4/14/2010 Underperform 5Y $4.65 -41.51% +120.49% +161.99 0 Comment
supez2004 < 20 3/3/2008 Underperform NS $5.75 -52.70% +107.57% +160.27 2 Comments
stockjock11 < 20 4/22/2010 Underperform NS $4.19 -35.08% +121.33% +156.42 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.00 6/27/2016 Outperform 3W $5.78 -52.94% +32.86% -85.80 0 Comment
TrackJimCramer 85.00 11/10/2014 Underperform 3W $16.43 -64.82% -2.15% +62.67 6/27/2016 @ $5.78 0 Comment
TrackFBRCapitalM 85.80 9/8/2014 Underperform NS $15.82 -82.81% +31.98% +114.79 0 Comment
TrackJimCramer 85.00 10/1/2013 Outperform 3W $10.39 +58.13% +20.46% +37.68 11/10/2014 @ $16.43 0 Comment
TrackJPMorgan 86.68 6/19/2013 Outperform NS $8.12 -66.50% +60.13% -126.64 0 Comment
TrackJimCramer 85.00 3/8/2013 Underperform 3W $7.38 +40.79% +8.94% -31.84 10/1/2013 @ $10.39 0 Comment
TrackUltraLong < 20 2/8/2013 Underperform NS $6.75 -59.70% +75.36% +135.06 1 Comment
TrackRothCapital 75.84 5/10/2012 Outperform NS $1.71 +59.06% +94.02% -34.95 0 Comment
TrackOppenheimer 62.44 5/17/2011 Outperform NS $4.92 -44.72% +99.85% -144.56 0 Comment
trackmlvcapital < 20 5/6/2011 Outperform NS $4.66 -41.63% +96.52% -138.15 0 Comment
TrackJMP 84.57 3/16/2011 Outperform NS $4.40 -38.18% +106.51% -144.69 0 Comment
TrackLadenburg < 20 5/11/2010 Outperform NS $6.03 -71.97% +21.31% -93.28 4/3/2012 @ $1.69 0 Comment
TrackRodmanRen < 20 3/2/2010 Outperform NS $2.64 +3.03% +135.99% -132.96 0 Comment
TrackRothCapital 75.84 2/25/2010 Outperform NS $2.40 +104.17% +23.95% +80.22 5/3/2011 @ $4.90 0 Comment
TrackBearStearns < 20 9/17/2009 Underperform NS $1.88 -24.47% +30.13% +54.60 4/17/2012 @ $1.42 0 Comment
TrackBreanMurray 48.06 9/16/2009 Outperform NS $1.88 +44.68% +151.13% -106.45 0 Comment
TrackPZK < 20 9/16/2009 Outperform NS $1.88 -24.47% +30.13% -54.60 4/17/2012 @ $1.42 0 Comment
TrackRodmanRen < 20 6/11/2007 Outperform NS $10.65 -92.96% -14.22% -78.73 3/10/2008 @ $0.75 0 Comment
TrackBofASec 91.84 11/2/2006 Outperform NS $13.51 -95.11% -5.05% -90.06 3/11/2008 @ $0.66 0 Comment

Advertisement